

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|-------------------------|
| Name of entity | Little Green Pharma Ltd |
| ACN | 615 586 215 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|---------------------------|
| Name of Director | Angus McDougall Caithness |
| Date of last notice | 21 February 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct & indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Banquo Consulting Pty Ltd - Mr Caithness is a director |
| Date of change | 17 December 2020 |
| No. of securities held prior to change | <u>Direct</u> 177,491 Ordinary shares 3,500,000 Options exercisable at 30 cents, expiring 28 February 2022 500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights <u>Indirect</u> 5,500,000 Ordinary shares 500,000 Class B Performance Rights |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| Class | Director Share rights |
| Number acquired | 115,516 Director Share Rights |
| Number disposed | Nil |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Nil consideration. Issued in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 3G dated 17 December 2020 |
| No. of securities held after change | <u>Direct</u> 177,491 Ordinary shares 3,500,000 Options exercisable at 30 cents, expiring 28 February 2022 500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights 115,516 Director Share Rights <u>Indirect</u> 5,500,000 Ordinary shares 500,000 Class B Performance Rights |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of Director Share Rights as approved by shareholders on 26 November 2020 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|-------------------------|
| Name of entity | Little Green Pharma Ltd |
| ACN | 615 586 215 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|------------------------|
| Name of Director | Fleta Jennifer Solomon |
| Date of last notice | 21 February 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | N/A |
| Date of change | 17 December 2020 |
| No. of securities held prior to change | 19,600,000 ordinary shares 500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights |
| Class | Director Share rights |
| Number acquired | 114,716 Director Share Rights |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| Number disposed | Nil |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Nil consideration. Issued in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 3G dated 17 December 2020 |
| No. of securities held after change | 19,600,000 ordinary shares 500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights 114,716 Director Share Rights |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of Director Share Rights as approved by shareholders on 26 November 2020 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|-------------------------|
| Name of entity | Little Green Pharma Ltd |
| ACN | 615 586 215 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------------|
| Name of Director | Michael David Lynch-Bell |
| Date of last notice | 21 February 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| Date of change | 17 December 2020 |
| No. of securities held prior to change | 600,000 Ordinary shares |
| Class | Director Share Rights and Retention Share Rights |
| Number acquired | 300,000 Retention Share Rights 150,917 Director Share Rights |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Director Share Rights - Nil consideration. Issued in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 3G dated 17 December 2020. Retention Share Rights – Nil consideration. |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| No. of securities held after change | 600,000 Ordinary shares 300,000 Retention Share Rights 150,917 Director Share Rights |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of Director Share Rights and Retention Share Rights as approved by shareholders on 26 November 2020 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|-------------------------|
| Name of entity | Little Green Pharma Ltd |
| ACN | 615 586 215 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------|
| Name of Director | Neale William Fong |
| Date of last notice | 21 February 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee |
| Date of change | 17 December 2020 |
| No. of securities held prior to change | Riverpalm Pty Ltd <NW Fong Family Trust> 250,000 Ordinary shares Dr Neale Fong <Damblock Trust> 675,000 Ordinary shares |
| Class | Director Share rights and Retention Share Rights |
| Number acquired | 150,000 Retention Share Rights 75,458 Director Share Rights |
| Number disposed | Nil |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Director Share Rights - Nil consideration. Issued in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 3G dated 17 December 2020. Retention Share Rights – Nil consideration. |
| No. of securities held after change | Riverpalm Pty Ltd <NW Fong Family Trust> 250,000 Ordinary shares Dr Neale Fong <Damblock Trust> 675,000 Ordinary shares 150,000 Retention Share Rights 75,458 Director Share Rights |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of Director Share Rights and Retention Share Rights as approved by shareholders on 26 November 2020 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.